Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Nothing short of miraculous....
View:
Post by wildbird1 on Dec 12, 2021 12:48pm

Nothing short of miraculous....

When TLT said" Comparing the 90 days and the 180 days assesment data, demonstrate that once a patients has obtained CR(Complete Response) or PR the duration of the response remain fairly durable".

Optimized Patients...
What the above mean is as we speak the potential CR(Complete Response) % is around 94.4 % at 90 days for the optimized patients. Knowing that the the CR % remain fairly durable, just to be on the safe side... TLT optimized patients could easily acheive 75 to 85% CR(Complete Response) at 180,260 ...days (that would be huge not to say humongous).

The big question is... Why is it that the optimized patients remain cancer free after 90,180,260...days????

To find a possible answer we have to go back to 2014 (TLT was doing preclinical studies).
PressRelease June 24,2014
PressRelease Nov  12, 2014
TLT said " TLT PDC technology demonstrates an ability to effectively destroy both Normoxix and Hypoxix cancer cells, this suggest an application of this technology to virtually all cancers, including later stage cancers(Bladder BCG resistant patients), that present with Hypoxix area and cores that can prove resistant to most form of treatment, also the ability of TLT PDC to destroy the original cancer and also program the body's immune system  to prevent its recurence, after only one single treatment, is nothing short of miraculous".

The above could be the reason for the durable response.

TLT treatment doesn't just cure the cancer...it can also program the immune system of the patient to fight recurrence on its own.

No wonder FDA gave fast-track designation to TLT.

How much money a big pharma Partner will be willing to pay, to be TLT partner in commercialization of this miraculous cancer treatment that could work virtually on all cancers.

All bets are open.
Comment by robertshaw on Dec 12, 2021 1:16pm
4 years ago, when we were in Phase 1 human trial stage, I once claimed after we see the 5th patient passed the 180 days cancer free, we would see 270 days cancer free data for sure as just weeks before the news of 5th patient 270 days cancer free data out, (I said that's my point of view from my experience as a chemist of over 30 years), Blowjobjoe then argued with me and put a bet against my ...more  
Comment by menoalittle on Dec 12, 2021 2:00pm
>> Blowjobjoe's bosses are our deadly enemy. quite frankly, it doesn't concern me... because without respect to if, when or how any supression (or oppression) of TLT's share price (or progress towards commercialization) has and might continue to occur, there is no doubt in my mind that a far bigger whale will overwhelm and cripple whoever or whatever "blowjobjoe's ...more  
Comment by Longholder99 on Dec 12, 2021 2:29pm
menoalittle.....is often correct. In this case I REALLY hope you are. Would love to see it happen all by surprise. Halt followed by big SP.jump after a nice BTD and partner announcement. Clean out the shorters bank acct. Would serve them right. Playing with fire.
Comment by CancerSlayer on Dec 13, 2021 4:44am
  Nice post.... And the administration of a personalized anti-cancer vaccine "post" treatment (whether it be a standard of care treatment or TLT's ACT) will have the potential to increase overall survival in the more deadly cancers...as was previously demonstrated in GBM rat models.   Giving an immune boost to an already triggered immune system would provide TLT another ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250